Type and hit ENTER

ProAxsis specialises in four key areas of business:

Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
Academic and Pharmaceutical Company Researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
ProAxsis R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.


ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, NEATstik®, at the European Respiratory Society Conference, which is taking place this week in Paris, France. Details of the presentation are below:   A novel point of care test for …

September 18, 2018

ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces that it has successfully registered a CE Mark for its novel ProteaseTag® Active Proteinase 3 Immunoassay. Furthermore, the company confirms an immediate first commercial sale for …

August 2, 2018

ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st 2018 in Birmingham, UK.  These include: • The Development of a Novel Immunoassay for the Detection and Quantification of Murine Neutrophil Elastase (Ashleigh Kennedy) • Sputum Storage Conditions and their …

June 18, 2018
ProAxsis | developing products for the capture, detection and measurement of active protease biomarkers of disease